--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About MRNA20260402P47
Biological Technology
Moderna, Inc., was incorporated under the laws of the State of Delaware on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (messenger ribonucleic acid) medicine. Through more than a decade of work at the intersection of science, technology and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective Covid-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset to responsibly change the future of human health, the company strives to deliver the greatest possible impact to people through mRNA medicines.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
